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Abstract: When COVID-19 was declared a pandemic, there was concern that TB and HIV services
in Zimbabwe would be severely affected. We set up real-time monthly surveillance of TB and
HIV activities in 10 health facilities in Harare to capture trends in TB case detection, TB treatment
outcomes and HIV testing and use these data to facilitate corrective action. Aggregate data were
collected monthly during the COVID-19 period (March 2020–February 2021) using EpiCollect5 and
compared with monthly data extracted for the pre-COVID-19 period (March 2019–February 2020).
Monthly reports were sent to program directors. During the COVID-19 period, there was a decrease
in persons with presumptive pulmonary TB (40.6%), in patients registered for TB treatment (33.7%)
and in individuals tested for HIV (62.8%). The HIV testing decline improved in the second 6 months
of the COVID-19 period. However, TB case finding deteriorated further, associated with expiry of
diagnostic reagents. During the COVID-19 period, TB treatment success decreased from 80.9 to
69.3%, and referral of HIV-positive persons to antiretroviral therapy decreased from 95.7 to 91.7%.
Declining trends in TB and HIV case detection and TB treatment outcomes were not fully redressed
despite real-time monthly surveillance. More support is needed to transform this useful information
into action.
Keywords: COVID-19; Zimbabwe; Harare; presumptive tuberculosis; tuberculosis; TB treatment
outcomes; HIV; antiretroviral therapy; EpiCollect5; operational research
1. Introduction
In early January 2020, a new coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), was linked to a series of atypical pneumonia cases reported
the previous month in Wuhan city, Hubei province, China. The virus spread rapidly
within China, and then onto Europe, the United States of America (USA) and the rest
of the world, causing the disease known as COVID-19. On 11 March 2020, the World
Health Organization (WHO) declared COVID-19 to be a global pandemic. By the end of
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2020, 80 million confirmed cases and 1.8 million deaths had been reported globally to the
WHO, making COVID-19 the leading cause of death among infectious diseases [1]. In
April 2020, one month after the pandemic had been declared, the epicenters were China,
Europe and the USA, and with large volumes of air traffic between these regions and Africa,
sub-Saharan Africa was predicted to be the next region to be hard hit by COVID-19 [2,3].
At the start of the COVID-19 crisis, political attention, resources and finances were
redirected within the health sector to help it grapple with the escalating numbers of
COVID-19 cases. National and local lockdowns restricted movement and forced people
to spend more time indoors, limiting access to health facilities. All of this raised concern
that countries with high burdens of tuberculosis (TB) and human immunodeficiency
virus/acquired immune deficiency syndrome (HIV/AIDS) might see interruption of health
services and poor quality of care for their patients [4]. Modeling studies suggested that
deaths due to HIV/AIDS and TB could increase by up to 10 and 20%, respectively, with the
greatest impact on HIV resulting from interruption to antiretroviral therapy (ART) and the
greatest impact on TB resulting from delayed diagnosis and treatment of new cases [5].
Similarities were drawn with the Ebola virus disease outbreak in Sierra Leone and
Liberia in 2014. Through restrictions in travel, zonal quarantines and understandable
community fear of health facilities, the ability of the national TB programs to diagnose
TB and continue with HIV testing of their TB patients was adversely affected, and, in
the case of Liberia, there was a decline in the rates of TB treatment success [6,7]. HIV
testing in the general population and in health facilities decreased in both countries,
although access to ART remained unaffected [8,9]. Early on in the COVID-19 pandemic,
the Stop TB Partnership and WHO issued guidance about how people with TB could
protect themselves and how national TB programs might adjust to COVID-19 outbreaks
and national/local lockdowns [10,11]. The United Nations Joint Programme on HIV/AIDS
(UNAIDS) provided similar advice and guidance to people living with HIV [12]. This
global advice was augmented by urgent calls for practical planning to tackle the growing
threat of COVID-19 in sub-Saharan Africa [13].
The first COVID-19 case reported to WHO by Zimbabwe was on 21 March 2020. By 15
April, Zimbabwe had reported 18 COVID-19 cases (with three deaths) [14], and the country
had gone into national lockdown. The impact that this would have on public health services
for the management of TB and HIV/AIDS was unknown. The Zimbabwe National TB
Programme (NTP) and National HIV/AIDS Programme (NAP) began preparations for the
continued delivery of TB-HIV services in this new environment of restricted movement [15].
The country also drew on the example of Guinea in West Africa, which garnered resources
to weather the Ebola virus disease storm and managed to maintain TB services despite
numerous obstacles [16].
The Zimbabwe NTP and NAP, working in close collaboration with the International
Union Against Tuberculosis and Lung Disease (The Union), the Special Programme for
Research and Training in Tropical Disease at WHO (TDR) and Vital Strategies, decided to
strengthen the routine and real-time monitoring and evaluation system for TB and HIV
case detection. The quarterly (3-monthly) recording and reporting system was supported
in selected health facilities in the capital city of Harare by recording and reporting every
month. It was hypothesized that if there were declines seen in persons presenting with
presumptive TB or in numbers registered and treated for TB, or decreases in persons
presenting for HIV testing or in numbers of HIV-positive persons being referred for ART,
then programs could act more quickly on monthly information rather than quarterly
information to reverse these trends.
The overall aim of the study was to determine the impact of the COVID-19 pandemic
on TB case detection, diagnosis and treatment outcomes and on HIV testing and referral to
ART through strengthened real-time surveillance. In selected health facilities in Harare,
Zimbabwe, specific objectives were on a monthly basis to: (i) document the cumulative
monthly increase nationally in COVID-19 cases and deaths and the effects on general health
services; (ii) collect, collate and report on specific TB and HIV-related data during the
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COVID-19 period (March 2020 to February 2021), (iii) document any specific programmatic
responses at the national and local level to TB and HIV diagnosis and treatment during
the COVID-19 period and (iv) compare the findings during the COVID-19 period with
data collected and collated retrospectively during the pre-COVID-19 period (March 2019 to
February 2020).
2. Materials and Methods
2.1. Study Design
This was a cohort study using programmatically collected aggregate data.
2.2. Setting
2.2.1. General Setting: Zimbabwe and Harare
Zimbabwe is a low-income country in southern Africa with an estimated population
of 14.6 million in 2019 and a gross national income per capita of USD 1390 [17,18]. About
70% of the population live below the poverty line. Zimbabwe is among the top 14 countries
globally with a triple burden of TB, HIV and multidrug-resistant TB [19].
Harare is the capital city with an estimated population of 1.5 million [20]. The current
study took place in Harare for two main reasons. The majority of cases of COVID-19
came from this area at the onset of the pandemic, and travel around the country was
extremely difficult due to quarantine and prohibited travel outside of the city during the
initial lockdown. Harare city consists of 8 districts, that include 46 public health facilities,
of which 44 are under the Harare City Health Department. These provide general health
services integrated with TB and HIV services whilst the other two are government central
hospitals which provide specialized health services. Of the 44 public health facilities
under the Harare City Health Department, 13 are polyclinics which additionally provide
maternity services, 29 are satellite clinics and 2 are infectious disease hospitals (of which
one became reserved as the city’s COVID-19 isolation center). Through stratified non-
proportional sampling from each district, ten health facilities (nine polyclinics and one
satellite clinic) were selected from a list of high-volume health facilities based on more than
1000 patients receiving life-long ART as a proxy for the volume of presumptive TB patients
seen per year. The established staff who were already working in these sites delivering
general health services and TB and HIV services assisted with the monthly collection
of data.
2.2.2. TB and HIV Services
The diagnosis and treatment of TB and HIV/AIDS in Zimbabwe are the responsibility
of the NTP and the NAP, respectively, under the Ministry of Health and Child Care (MO-
HCC). People with symptoms suggestive of TB (typically, cough, fever, weight loss and
night sweats) are classified as having presumptive TB when they attend a health facility.
They are recorded as such in the presumptive TB register along with their demographic
details. In the Harare city clinics, sputum samples are collected and sent to an onsite
laboratory at each polyclinic, except satellite clinics that submit specimens to a laboratory
at the nearest polyclinic. In the laboratories, patient details and sputum results are entered
in the laboratory register. Investigations are carried out according to national and interna-
tional guidelines [21,22], using the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA)
and/or sputum smear microscopy to establish a bacteriologically confirmed diagnosis of
pulmonary TB (PTB), and results are sent back for patient tracking.
Those patients with a negative sputum result but who still have TB-related symptoms
are referred to see a doctor at either of the two nearest infectious disease hospitals where
clinical assessments, radiography and other circumstantial evidence are used to establish a
diagnosis of clinically diagnosed PTB or extrapulmonary TB (EPTB). These patients are
started on TB treatment before referral back to their initial health facility for registration
and continuation of TB treatment. Patients with diagnosed TB are registered in the health
facility Directly Observed Treatment (DOT) register and started on anti-TB treatment
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in accordance with national and international guidelines [21,22]. In the selected health
facilities in Harare, patients with drug-susceptible TB (DS-TB) are treated and monitored
with the standard 6-month regimens, while those with the drug-resistant disease are treated
and monitored with MDR-TB regimens. Patients with drug-resistant TB were not included
in this study. Treatment outcomes are monitored, recorded and reported according to
international guidelines [23].
HIV testing takes place in public health facilities and is routinely offered to anyone
attending for care, including TB patients, according to national and international guide-
lines [24–26]. HIV testing is carried out using rapid testing algorithms in line with WHO
guidance, and test results are entered in the HIV Testing Services (HTS) register that is
placed at all health service delivery points. Once patients are diagnosed positive for HIV,
they are retested for verification of HIV diagnosis and, if confirmed HIV-positive, they are
then prepared and counseled for ART and referred for immediate start of ART regardless
of WHO clinical stage or CD4 cell count. Administration of an HIV screening tool for HIV
risk assessment before providing a rapid HIV test and use of HIV self-testing are measures
that have been scaled up recently to improve the HIV positivity yield.
There is generally good quality data capture and reporting for TB and HIV/AIDS at
all levels due to regular supervision by national program supervisors.
2.2.3. Data Monitoring, Recording and Reporting for the Study in Health Facilities
in Harare
Data were routinely collected daily by front-line health workers. They provided
services in each of the ten health facilities in Harare using the standard MOHCC monitoring
tools (presumptive TB register, sputum laboratory register, TB patient register and HTS
register), most of which were paper-based. One to two weeks after the end of each
month, the project country coordinator (KCT—who was appointed specifically for the
study) visited each site along with his team of trained data collectors. They collated the
individual data on TB and HIV variables for the previous month into monthly aggregate
data, which they then entered into a proforma developed using an EpiCollect5 application
(https://five.epicollect.net, accessed on 29 May 2021).
For TB treatment outcomes, the monthly cohorts of patients enrolled onto treatment
eight months previously were used—this allowed for six months of treatment to be com-
pleted and a further two months for outcomes to be validated and recorded in the registers.
For example, the October 2020 TB treatment outcome data were obtained for TB patients
enrolled and started on treatment in February 2020. This allowed for clear separation of
treatment cohorts in the pre-COVID-19 and COVID-19 periods.
National data on COVID-19 cases and deaths reported to WHO on the last day of the
month were obtained from WHO situation and epidemiological reports [1].
When the prospective monthly data were collected, a schedule and the same proce-
dures were used to collect retrospective data. For each month of the COVID-19 period
(March 2020 to February 2021), data were collected on TB and HIV parameters for a
matching period one year before the COVID-19 period (March 2019 to February 2020).
Once all prospective and retrospective data for the month had been entered into
EpiCollect5, they were checked and validated by both the project country coordinator and
the overall project monitoring and evaluation officer (PT) based at The Union. Data were
then presented in a monthly report as a series of figures and tables and narrative to the
directors of the NTP and NAP and to all other relevant stakeholders involved in the project.
Key policy or practice changes made at the local health facility or at the national level
during that month to explain and/or counteract the effects of COVID-19 on TB and HIV
parameters were recorded in a narrative table within the report. These monthly reports
were always sent and received by the national program staff within four weeks of closure
of that month to enable timely surveillance and possible action.
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2.3. Study Population
The study population included all patients presenting to TB services with presumptive
TB, all TB patients registered for DS-TB treatment and all persons tested for HIV between
March 2019 and February 2021; March 2020 to February 2021 was the COVID-19 period,
and March 2019 to February 2020 was the pre-COVID-19 period. We also included TB
patients registered for treatment eight months prior to the study period to assess treat-
ment outcomes.
2.4. Data Variables, Sources of Data and Timing of Data Collection
Data variables for TB included aggregate numbers of patients: with presumptive
PTB, stratified by male and female, adults (≥15 years) and children (<15 years); who
were diagnosed with bacteriologically positive PTB by either smear microscopy and/or
Xpert MTB/RIF; with registered TB, stratified by bacteriologically confirmed PTB, clinically
diagnosed PTB and EPTB; and with registered TB, who were newly tested for HIV in that
month after being diagnosed with TB—this excluded patients who already knew they were
HIV-positive or had recently been diagnosed HIV-negative. Standardized TB treatment
outcomes of those patients enrolled for treatment eight months previously were collected
and included—treatment success (a combination of those cured and those who completed
treatment with no sputum smear examination), lost to follow-up (LTFU), died, failed
treatment or not evaluated [23]. LTFU refers to a TB patient who did not start treatment or
whose treatment was interrupted for two consecutive months or more. Not evaluated is an
outcome given to those who transfer from one facility to another and for whom the final
treatment outcome is not recorded and also to those whose outcome is not recorded and
unknown to the reporting unit.
Data variables for HIV included: persons who were HIV tested at the health facili-
ties, stratified by male and female, adults (≥15 years) and children (<15 years); persons
diagnosed HIV-positive; and HIV-positive persons referred to ART services.
Sources of data were the presumptive TB register, the sputum laboratory register, the
TB patient register, and the HTS register. Prospective and retrospective data for the study
were collected between June 2020 and March 2021.
2.5. Analysis and Statistics
Aggregate data were entered in EpiCollect5, where they were checked and validated
in-country by the country coordinator and by The Union’s monitoring and evaluation
officer. Data were presented as frequencies and proportions, and comparisons were made
between the COVID-19 period and the pre-COVID-19 period. The percentage decline
in numbers during each month of the COVID-19 period was calculated relative to the
numbers during the same month of the pre-COVID-19 period. The relative percentage
differences observed between the first 6 months of COVID-19 (March to August 2020) and
the second 6 months of COVID-19 (September 2020 to February 2021) were also calculated.
3. Results
3.1. COVID-19 Cases and Deaths and General Effects on Health Services
COVID-19 cases and deaths as reported to WHO cumulatively increased to 35,994
and 1458, respectively, during the 12 months (see Figure 1).
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night curfews, health facilities shortened their working hours, and some health facilities 
had to close due to either shortage of health care workers or if there was an outbreak of 
COVID-19 within the facility. Only a few patients were allowed into health facilities at a 
time, resulting in long waiting queues outside, which may have deterred patients from 
coming to the health facilities. Between July and September 2020, there was industrial 
strike action again in the health sector over the lack of personal protective equipment and 
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activities, including recording and reporting. There was widespread community fear 
about contracting COVID-19 or being diagnosed with COVID-19 at health facilities during 
the whole period. 
From a TB perspective, environmental health technicians, responsible for community 
follow-up of TB patients while on treatment, were repurposed to COVID-19 activities. 
Between 12 December 2020 and 11 January 2021, GeneXpert cartridges expired in some 
facilities, and during this time clinic staff did not collect sputum specimens for TB inves-
tigation. 
From an HIV perspective, voluntary male medical circumcision services (VMMC), 
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From a TB perspective, environmental health technicians, responsible for community
follow-up of TB patients while on treatment, were repurposed to COVID-19 activities.
Between 12 December 2020 and 11 January 2021, GeneXpert cartridges expired in some facil-
ities, and during this time clinic staff did not collect sputum specimens for TB investigation.
From an HIV perspective, voluntary male medical circumcision services (VMMC), which
provided HIV testing for a large number of male adolescents and men, stopped in March
2020 and remained closed for the next 12 months. There were stock-outs of HIV test kits in
July 2020, which remained a challenge intermittently for the next few months.
3.2. TB Case Finding, Diagnosis and Registration
There was an overall decrease in the numbers of persons presenting with presumptive
PTB (40.6%), people diagnosed with bacteriologically confirmed PTB (30.1%) and people
being registered for TB treatment (33.7%) in the COVID-19 period compared to the pre-
COVID-19 period (Table 1).
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Table 1. Characteristics of persons with presumptive pulmonary TB and registered TB in 10 health facilities in Harare,











Presumptive pulmonary TB: 3270 1941 ↓40.6
Adults (≥15 years) 3013 1849 ↓38.6
Children (<15 years) 181 52 ↓71.3
Male 1866 1150 ↓38.4
Female 1221 782 ↓36.0
Bacteriologically positive 442 309 ↓30.1
Positivity rate (%) (13.5%) (15.9%) ↑2.4% *
Registered TB: 1078 715 ↓33.7
Bacteriologically confirmed PTB 528 346 ↓34.5
Clinically diagnosed PTB 465 251 ↓46.0
Extrapulmonary TB 136 97 ↓28.7
Eligible for being newly HIV tested 586 423 ↓27.8
Newly tested for HIV (%) (95.1%) (90.3%) ↓4.8% *
* absolute change (increase or decrease); TB = tuberculosis; PTB = pulmonary tuberculosis; ↑ = increase; ↓ = decrease.
For presumptive PTB, the overall decrease was greater in children (71.3%) compared
with adults (38.6%), but almost similar between males (38.4%) and females (36.0%). The
yield of bacteriologically positive PTB in those investigated for presumptive TB increased
from 13.5 to 15.9%. The decline in those diagnosed and registered with TB was worse for
patients with PTB, and amongst those with pulmonary disease, it was worse for those with
clinically diagnosed PTB (46.0%). The proportion of TB patients tested for HIV remained
above 90%, although it declined from 95.1 to 90.3%.
The monthly numbers of persons presenting with presumptive PTB and registered TB
in the pre-COVID-19 and COVID-19 periods are shown in Figure 2A,B. The footnotes for the
Figures indicate the interventions that were put in place to counteract the downward trends.
Compared with the pre-COVID-19 period, the decline in presumptive TB in the first 6
months of COVID-19 (March to August 2020) was 35.8%, and this became greater in the
second 6 months (September 2020 to February 2021) when the decline was 45.5%. The
decline in registered TB in the first 6 months of COVID-19 was 29.9%, which also became
greater in the second 6 months when the decline was 37.5%.
3.3. TB Treatment Outcomes
The overall aggregate treatment outcomes between the pre-COVID-19 and COVID-19
periods are shown in Table 2. There was a decrease in treatment success from 80.9 to 69.3%,
mainly due to an increase in patients “not evaluated” (12.1%). Other program outcomes
were similar between the two periods.
The monthly treatment success rates in the pre-COVID-19 and COVID-19 periods are
shown in Figure 3. Interventions to reverse downward trends are indicated in the footnotes.
Compared with the pre-COVID-19 period, the decline in treatment success was 14% in the
first 6 months of COVID-19. This improved in the second 6 months when the decline was
7.8%. Treatment success particularly improved in January and February 2021 to 80 and
78%, respectively.
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persons presenting with registered TB in 10 health facilities in Harare, Zimbabwe, during pre-
COVID-19 and COVID-19 periods.  = increase;  = decrease. Interventions applied from July 
2020 onwards to counteract the decline in numbers included: integrated screening of patients with 
respiratory symptoms for TB and COVID-19; improved contact tracing of index patients with TB 
and COVID-19; and strict infection control practices at health facilities which were promoted to try 
and encourage symptomatic patients to attend. 
3.3. TB Treatment Outcomes 
The overall aggregate treatment outcomes between the pre-COVID-19 and COVID-
19 periods are shown in Table 2. There was a decrease in treatment success from 80.9 to 
Figure 2. (A): Monthly nu bers of persons presenting ith presu ptive PTB in 10 health facilities in
Harare, Zimbabwe, during pre-COVID-19 and COVID-19 periods. (B): Monthly numbers of persons
presenting with registered TB in 10 health facilities in Harare, Zimbabwe, during pre-COVID-19
and COVID-19 periods. ↑ = increase; ↓ = decrease. Interventions applied from July 2020 onwards
to counteract the decline in numbers included: integrated screening of patients with respiratory
symptoms for TB and COVID-19; improved contact tracing of index patients with TB and COVID-19;
and strict infection control practices at health facilities which were promoted to try and encourage
symptomatic patients to attend.
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Table 2. Treatment outcomes of patients enrolled in TB treatment in 10 health facilities in Harare, Zimbabwe, during
pre-COVID-19 and COVID-19 periods.
Treatment Outcomes in Patients










Enrolled for treatment: 1210 979
Treatment success (%) (80.9) (69.3) ↓11.6 *
Lost to follow-up (%) (2.0) (2.3) ↑0.3 *
Died (%) (4.3) (3.7) ↓0.6 *
Failed (%) (0.6) (0.4) ↓0.2 *
Not evaluated (%) (12.2) (24.3) ↑12.1 *
* absolute change (increase or decrease); TB = tuberculosis; ↑ = increase; ↓ = decrease; treatment outcome was considered “treatment
success” when the TB patient was either cured or had “treatment completed”. The success rate was calculated for the month-wise cohort
of TB patients commenced on treatment eight months prior to the reporting month (this takes account of six months of treatment to be
completed and another two months to finalize the recording of the final treatment outcome).
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Figure 3. Treatment success amongst patients enrolled each month in 10 health facilities in Harare,
Zimbabwe, during pre-COVID-19 and COVID-19 periods. Enrollment occurred eight months prior
to the month of reporting (to allow for 6 months treatment and 2 months of follow-up and record the
final outcome); ↑ = increase; ↓ = decrease. The interventions applied from July onwards included:
medication refills given for longer periods and synchronized for TB and ART medicatio s; attempts
to reduce the outcome “not evaluat d”.
3.4. HIV Testing and Referral to ART
There was a large overall decrease in numbers tested for HIV between pre-COVID-19
and COVID-19 periods (Table 3). The overall decrease was greater for children (70.2%)
compared with adults (62.4%) and greater for males (79.1%) compared with females (53.6%).
There was a small relative increase in the HIV positivity rate from 6.0 to 8.1% and a small
decrease in the referral of HIV-positive persons to ART from 95.7 to 91.7% during the
COVID-19 period.
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Table 3. Characteristics of persons tested for HIV and referred to antiretroviral therapy in 10 health facilities in Harare,











Underwent HIV testing at a health facility: 51,078 18,987 ↓62.8
Adults (≥15 years) 48,661 18,289 ↓62.4
Children (<15 years) 2316 691 ↓70.2
Male 18,278 3816 ↓79.1
Female 32,706 15,171 ↓53.6
Positive for HIV 3045 1547 ↓36.7
HIV positivity rate (%) (6.0%) (8.1%) ↑2.1 *
Referred to ART (%) (95.7%) (91.7%) ↓4.0 *
* absolute change (increase or decrease); ↑ = increase; ↓ = decrease; ART = antiretroviral therapy.
The monthly numbers tested for HIV in the pre-COVID-19 and COVID-19 periods are
shown in Figure 4.
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Figure 4. Monthly numbers presenting each month for HIV testing in 10 health facilities in Harare,
Zimbabwe, during pre-COVID-19 and COVID-19 periods; ↑ = increase; ↓ = decrease. From August
2020 onwards, human resources support was given to the Ministry of Health by PEPFAR partners
(President’s Emergency Fund for AIDS Relief in Africa) by seconding direct service delivery nurses
to affected sites.
The number of people being HIV tested in health facilities was already declining in the
pre-COVID-19 period due to a number of factors that included: a shift from general HIV
testing to more targeted HIV testing using a screening tool to identify high-risk groups,
to identify those with a high lifestyle risk score assessment and to identify those who had
not been tested in the previous year; promotion of HIV self-testing, with the referral of
only those HIV-positive to the health facilities for confirmation of the result; and a greater
focus on index partner testing. As explained in the footnotes of Figure 4, human resources
support was provided to clinics from August 2020 onwards to sustain HIV testing services
and ART delivery. Compared with the pre-COVID-19 period, the decline in HIV testing
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in the first 6 months of COVID-19 was 62.8%, which was greater than the 37.6% decline
observed in the second 6 months.
4. Discussion
This is the first study in Zimbabwe to assess the impact of COVID-19 on TB and HIV
services in selected health facilities in Harare, the capital city. In summary, despite attempts
by the NTP, the NAP and other parts of the health sector to prepare for COVID-19 [15,27],
there was a large negative impact on almost all aspects of TB case detection, diagnosis and
treatment, as well as HIV testing. The referral of HIV-positive persons to ART was also
affected but only to a small degree. A health service already under strain was hit hard and
brought almost to its knees in the first 12 months of the COVID-19 pandemic [27].
With respect to TB program activities, the numbers of people presenting to health
facilities with presumptive PTB declined considerably over the 12-month COVID-19 period.
These findings were similar to those described in the early months of COVID-19 in clinics in
Tehran, Iran [28] and Nigeria [29], where lockdown restrictions, transportation difficulties
and community fear of health facilities were thought to hinder health facility access. There
was a corresponding decline in numbers diagnosed and registered with TB, in line with
reports from other countries where the decreases in TB case notifications in the early
months of COVID-19 compared with previous years were 48% in clinics in China [30], 48%
in clinics in Brazil [31] and 56% in India [32].
A modeling analysis at the start of the pandemic suggested that a 3-month suspension
of TB services due to COVID-19 lockdown followed by ten months restoration back to
normal would cause over five years an additional 1.2 million TB cases in India, 25,000
additional TB cases in Kenya and 4000 additional cases in Ukraine, mainly as a result of
the accumulation of undetected TB during lockdown [33]. Unfortunately, in Zimbabwe,
there was no restoration of services back to normal. On the contrary, from October 2020
to February 2021, there was a steady decline in numbers of persons with presumptive
PTB and registered TB, coinciding with the expiry of cartridges for Xpert MTB/RIF assays.
Sputum specimens were not collected for investigation, and patients with TB-related
respiratory symptoms stayed away. The one encouraging finding was an overall increase in
bacteriological positivity in the COVID-19 period compared with the previous year. There
are several possible explanations that include: (i) when laboratories were functioning and
reagents were available, standard laboratory operating procedures remained intact; (ii)
there was selective self-referral of only those who were really sick with TB; and (iii) patients
may not have had access to community TB testing services as a result of COVID-19, and
therefore those with TB came to Harare city health facilities for investigation.
TB treatment success rates declined during the COVID-19 pandemic. However, there
was some improvement in the second half of the year, and particularly in January and
February 2021, when outcomes were better than at the corresponding times before COVID-
19. The probable reason for better outcomes at this time was, as discussed earlier, a series
of health care worker strikes towards the end of the pre-COVID-19 period as a result of
heightened economic decline. This disrupted routine follow-up of TB patients on treatment,
resulting in a high number of patients not being evaluated.
With the onset of the COVID-19 pandemic, we were concerned that COVID-19 re-
strictions would hinder patients collecting anti-TB medications and compromise drug
adherence. However, the longer periods given between anti-TB drug refills and their
synchronization with ART medication refills made things easier for patients and partly
mitigated this challenge. The large proportion of patients “not evaluated” was a huge
challenge, compromising the program’s ability to record successful treatment outcomes.
This was partly due to the environmental health technicians responsible for following up
patients in the community being repurposed to COVID-19 activities. Concerted efforts,
however, were made to tackle this issue, and through human resources support from PEP-
FAR (the President’s Emergency Plan for AIDS Relief), treatment success rates considerably
improved in the last two months.
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With respect to HIV services, there was a significant decrease in numbers of people
presenting for HIV testing, although this did improve during the latter half of the COVID-
19 period. There were two main reasons for the large decline. First, the cessation of VMMC
services would have resulted in a large decline in males being HIV tested during this time.
Second, in April 2020, during the national lockdown, the MOHCC issued a directive for all
community-based HIV testing to be temporarily halted to minimize the risk of community
health workers and community members from contracting COVID-19. The improvement
in the latter half of the COVID-19 period may have been due to the strong support from
PEPFAR partners.
The overall reductions in HIV testing were similar to what has been observed in
Europe [34], the USA [35] and Africa [36]. It is likely, though, that we have overestimated
the COVID-19 impact on HIV testing because of Zimbabwe adopting a more targeted ap-
proach, promoting HIV self-testing and focusing on index HIV testing before the onslaught
of COVID-19. The increase in HIV positivity observed in the COVID-19 period in our study
is probably a result of this more targeted approach to identifying clients more at risk of
HIV. While referrals to ART decreased in the COVID-19 period, it was encouraging to see
that they were still maintained at over 90%.
There are several strengths to this study. First, the real-time monthly surveillance was
embedded within the routine services of the health facilities, and there was cross-checking
and validation of the data each month between the country coordinator and the overall
study monitoring and evaluation officer. We believe, therefore, that the data were accurate
and reflected programmatic practice in the field in Harare. Second, we used two 12-month
periods to compare data, thus accounting for seasonal changes that might have affected TB
case detection and HIV testing. Third, the conduct and reporting of the study were in line
with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines [37].
However, there were some limitations. Our study was limited to health facilities
in Harare, and therefore may not be representative of Zimbabwe as a whole. The use
of aggregate quantitative data made it impossible to understand the cascade of care for
TB case detection and HIV testing during COVID-19. Further mixed-methods research
with both quantitative and qualitative analysis amongst TB patients themselves, as has
been conducted in Zambia [38], are needed to obtain a better idea of why patient access
to health services and health service delivery was so badly affected. We only assessed
referrals of HIV-positive persons to ART and did not document the initiation or retention
on ART. Previous studies have suggested that ART interruption has been a problem during
the COVID-19 pandemic [39]. It would have been interesting to assess this in Zimbabwe,
especially as interruption to ART is thought to be one of the most important determinants
of HIV-related mortality during the COVID-19 pandemic [40]. Finally, the official monthly
reports to WHO of COVID-19 cases and deaths may have underestimated the true burden
of COVID-19 in the country. A study on deceased people at the University Teaching
Hospital morgue in Lusaka, Zambia, found that just 9% of 70 people, who were confirmed
as having SARS-CoV-2 from postmortem nasopharyngeal swabs within 48 h of death, had
ever been tested before death [41]. This finding is unlikely to be confined to Zambia, and
large numbers of unreported cases and deaths due to COVID-19 are probably occurring in
other countries in Africa.
Despite these limitations, there are some important programmatic implications from
this study. First, the strengthened monthly surveillance system worked well with both
NTP and HIV program directors looking each month at the monthly reports and using the
data for decision making and suggesting interventions. The monthly data were also shared
with the ten health facilities through the country coordinator, and this enabled the health
facilities to implement interventions simultaneously. However, the monthly surveillance
and the interventions applied were insufficient to reverse the direct negative effects of
COVID-19 on services or the indirect effects such as industrial action and stock-outs of
diagnostic tests. Given the challenges both programs faced, it is remarkable that services
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were able to function at all, so without monthly surveillance, it might have been much
worse. The monthly surveillance as conducted in Harare required effort and external
support. If this became routine as desired, the NTP would require considerable investment,
probably involving electronic case-based reporting systems. Technical support by partners,
who have additional human resources to help, would be vital to get activities and services
back to normal.
Second, with COVID-19 likely to become endemic, there is an urgent need to bring TB
case detection and treatment outcomes back to pre-COVID-19 levels. This study suggested
that better contact tracing of TB patients and heightened attention to reducing the “not
evaluated” category were important interventions for TB case detection and TB treatment
outcomes. Support from PEPFAR partners also helped to support staff in ascertaining TB
treatment outcomes. There are several other suggestions about how TB services could
be sustained or improved in the face of the pandemic. These include: better integration
and screening of TB and COVID-19 at the health facility and community level; sharing
testing algorithms and multiplexing equipment such as GeneXpert platforms within the
laboratories; having robust procurement and delivery systems to avoid reagent stock-outs;
ensuring effective infection, prevention and control activities within health facilities; hav-
ing longer 3-month follow-up appointments for patient check-ups and drug collection;
providing health information education in health facilities and the community; and mobi-
lizing support networks of TB survivors and TB communities [42–44]. More use of digital
platforms for case finding, drug adherence, management of adverse drug reactions and
training have also been recommended as a way of rapidly restoring TB diagnosis, care
and prevention services [45]. The Zimbabwe NTP and MOHCC could consider which, if
any, of these innovative approaches might help, and might be feasible and cost-effective to
implement.
Third, HIV self-testing, index partner notification and home-based HIV testing services
have allowed HIV testing numbers in the COVID-19 era to rebound in some African
countries [46–48]. Zimbabwe is already moving in this direction. It is also vital to capture
all HIV testing and HIV test results outside of as well as within the health sector in order
to keep informed about what is happening and ensure that all HIV-infected persons are
able to initiate ART. Zimbabwe again is already implementing such an approach and is
tracking on a monthly basis facility and community distribution of HIV test kits, as well as
numbers tested for HIV along with their results. Further deployment of electronic data
capture systems will be important in this context.
Finally, the resources and funding that have been raised to fight the COVID-19 pan-
demic have been staggering. The proposed global financing systems that have been pro-
posed as a way of promoting and enabling science and product development in the health
sector [49] must be used and leveraged to help fight other diseases, TB and HIV/AIDS
included, so that we can stay on track to deliver on the Sustainable Development Goals
in 2030.
5. Conclusions
Using strengthened monthly real-time surveillance in 10 health facilities in Harare,
Zimbabwe, we documented that numbers of persons with presumptive PTB and registered
TB, treatment outcomes of patients enrolled on treatment and numbers being HIV tested
all declined during 12 months of the COVID-19 outbreak compared with 12 months pre-
COVID-19. The referral of HIV-positive persons to ART also declined, although they were
maintained at high levels throughout. Despite using the monthly data, the declining trends
in TB and HIV services could not be reversed because of on-going restrictions resulting
from the COVID-19 pandemic combined with industrial action in the health sector and the
expiry of certain diagnostic reagents. Suggestions have been made as to how to restore TB
case detection and HIV testing so that TB- and HIV-related morbidity and mortality can be
kept as low as possible during this difficult period.
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